Table IV.

ORs, interaction contrast ratios (ICRs) and 95% CI for six PPARA polymorphisms and breast cancer by aspirin use in all LIBCSP women under the dominant inheritance model

Interactionab	ORc	95% CI	ICR	95% CI
rs135542
AA*(aspirin use)d	0.92	0.69, 1.23
(AG + GG)*(non-use)	1.09	0.88, 1.36
(AG + GG)*(aspirin use)	0.56	0.39, 0.81	−0.45	−0.87, −0.04
rs1800206
CC*(aspirin use)	0.73	0.57, 0.92
(CG + GG)*(non-use)	1.05	0.71, 1.56
(CG + GG)*(aspirin use)	0.94	0.46, 1.89	0.16	−0.59, 0.91
rs4253623
AA*(aspirin use)	0.64	0.49, 0.84
(AG + GG)*(non-use)	0.94	0.73, 1.22
(AG + GG)*(aspirin use)	1.07	0.71, 1.61	0.48	−0.01, 0.98
rs4263699
TT*(aspirin use)	0.60	0.45, 0.80
(CT + CC)*(non-use)	0.85	0.66, 1.09
(CT + CC)*(aspirin use)	0.91	0.62, 1.32	0.46	0.08, 0.84
rs4253755
GG*(aspirin use)	0.65	0.50, 0.84
(AG + AA)*(non-use)	0.93	0.68, 1.27
(AG + AA)*(aspirin use)	1.08	0.67, 1.75	0.50	−0.05, 1.05
rs4253760
TT*(aspirin use)	0.62	0.47, 0.82
(GT + GG)*(non-use)	0.92	0.70, 1.21
(GT + GG)*(aspirin use)	0.97	0.65, 1.44	0.42	−0.01, 0.85

^aInteractions between aspirin use and each SNP were estimated using separate logistic regression models that also included main effect terms for the other PPARA SNPs. All ORs are estimated relative to a common referent group consisting of aspirin non-users with the referent genotype for each SNP. ICRs indicate departures from expectations for additive effects of aspirin use and each SNP on breast cancer risk.

^bMinor allele in bold.

^cAdjusted for age, measured in 5-year age intervals.

^dAspirin use was defined as use at least once per week for 6 months or longer.